You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. A2A receptor blockade for sepsis

    SBC: Purine Pharmaceuticals Inc.            Topic: NIAID

    SUMMARY Sepsis is a clinical syndrome that complicates severe infectionSepsis remains the leading cause of morbidity and mortality in critically ill patientsThere are no specific FDA approved medicines for the treatment of sepsisCurrent concepts of the pathophysiology of sepsis suggest that organ failure and mortality in sepsis are caused by inappropriate regulation of the immune systemThis manife ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. AC5 Inhibitor for Obesity

    SBC: VASADE BIOSCIENCES, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a drug that will be therapeutic for obesity and diabetes and improve exercise tolerance. Obesity, diabetes and exercise are inextricably linked such that an agent that improves exercise tolerance or prevents obesity or the development of diabetes will likely have a therapeutic role in all three conditions. Obesity is a gl ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. A cost-effective bioreactor to advance functional tissue engineering of cartilage

    SBC: Apex Biomedical Company, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Osteoarthritis (OA) is the leading cause of chronic disability in the United States. A clinical goal in the treatment and prevention of OA is to develop replacement cartilage using tissue engineering (TE) technologies. Although TE cartilage presently lacks the mechanical stability of native cartilage, studies have demonstrated that mechanical stability can be e ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Acute-infarct selective cardiac MRI contrast agent

    SBC: ELGAVISH PARAMAGNETICS, INC.            Topic: NHLBI

    DESCRIPTION provided by applicant The overall goal of this project is to demonstrate the ability of our acute myocardial infarct selective paramagnetic contrast agent Gadolinium ABE DTTA to differentiate between acute and chronic infarcts in a reliable manner using contrast enhanced magnetic resonance imaging ceMRI In our Phase I data we have shown that Gd ABE DTTA exclusively highlight ...

    STTR Phase II 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Additive Manufacturing Sensor Fusion Technologies for Process Monitoring and Control.

    SBC: ARCTOS Technology Solutions, LLC            Topic: DLA18A001

    Universal Technology Corporation (UTC) has teamed with the University of Dayton Research Institute (UDRI), Stratonics, and Macy Consulting to demonstrate not only the transitionability into commercial systems, but also to develop the data analytics and monitoring and control requirements to extract the full value fromseveral sensors, including the Stratonics ThermaViz, acoustic and profilometry se ...

    STTR Phase I 2018 Department of DefenseDefense Logistics Agency
  6. Additive Manufacturing Sensor Fusion Technologies for Process Monitoring and Control.

    SBC: ARCTOS Technology Solutions, LLC            Topic: DLA18A001

    This Phase II project aims to assemble the key set of sensor modalities that are needed to reliably view the key process anomalies and properties of laser powder bed fusion. The research team will down-select from the Phase I sensors investigated and integrate the sensors into a sensor fusion software package that facilitates data collection and synchronization, and eventually feedback control of ...

    STTR Phase II 2019 Department of DefenseDefense Logistics Agency
  7. A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy

    SBC: Neuro Devices, Inc.            Topic: 107

    DESCRIPTION provided by applicant We devised a new generation highly sensitivity method to diagnosis peripheral neuropathy early when the probability for reversal is greatest Cancer chemotherapy and diabetes are the most common causes of neuropathy in the USA Both cause decreased sweating abnormal circulation peripheral numbness pain and weakness If diagnosed early both are potentially ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Administrative Supplement to restore fee funds

    SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.            Topic: NINDS

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. A 3D Printed Resorbable Antimicrobial Envelope to Prevent Infection of Implanted Cardiac Devices

    SBC: N8 MEDICAL INC            Topic: NHLBI

    ABSTRACT Infection is a serious and potentially fatal complication of surgery to deliver cardiovascular implantable electronic devicesCIEDsi epacemakers and implantable cardioverter defibrillatorsUntreated device related infection is associated with mortality rates as high asCurrentlyonly one antibiotic impregnated mesh has been FDA approved for placement in surgical incisions to reduce infections ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. A dual histone deacetylase and glycogen synthase kinase 3 beta inhibitor for treating pancreatic adenocarcinoma

    SBC: Avenzoar Pharmaceuticals, Inc.            Topic: 102

    ABSTRACT Pancreatic cancer is a disease with no effective treatmentIt s low five year survival rateestimated at betweenandranks it the fourth highest of cancer related of death in the U Sdespite being the twelfth most common type of cancerEach year in the U Sthere are nearlynew cases and more thandeaths caused by the diseaseBypancreatic cancer is expected to be the second most common cancer relate ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government